PH Associated With Interstitial Lung Disease

This course will discuss pulmonary hypertension that is associated with interstitial lung disease. Participants will learn about its mechanisms of development, clinical features, diagnostics, and possible treatment options.

Course Author

Zeenat Safdar, MD
Assistant Professor of Medicine
Associate Director, Baylor PH Center
Pulmonary-Critical Care
Baylor College of Medicine
Houston, TX

Faculty Reviewers

Harrison W. Farber, MD
Professor of Medicine
Director, Pulmonary Hypertension Center
Boston University/Boston Medical Center
Boston, MA

Harold Palevsky, MD
Professor of Medicine
Chief, Pulmonary, Allergy, and Critical Care Division
Medical Director, Pulmonary Vascular Disease Program
Hospital of the University of Pennsylvania
Penn Presbyterian Medical Center
Philadelphia, PA

Learning Objectives

Upon successful completion of this course, participants will be able to:

1. Describe the mechanisms contributing to the development of PH in patients with Interstitial Lung Disease (ILD)
2. Restate clinical features associated with PH in ILD patients
3. Explain the diagnostic work up that should be undertaken in these patients
4. Demonstrate knowledge of possible treatment modalities for PH associated with ILD

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of College of Medicine, Mayo Clinic and the Pulmonary Hypertension Association (PHA). College of Medicine, Mayo Clinic is accredited by the ACCME to provide continuing medical education for physicians.

College of Medicine, Mayo Clinic, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Earning Credit

This activity is a self-study program. Upon entering the activity, participants should read the text, examine any images and/or multimedia features, and review the content presented within all of the links provided. Once the course has been reviewed in its entirety, participants will be asked to complete a post-test and evaluation online. Participants must receive a test score of 100% in order to proceed to the course evaluation; the post-test can be repeated until all questions are answered correctly. All evaluation questions must be completed in order to receive a certificate of credit. If needed, participants may save their answers and complete the course at a later date. Saved courses can be found on the "My Activities" page, accessed via "My Account" at the top of the page.

Faculty Disclosures

College of Medicine, Mayo Clinic adheres to ACCME Essential Areas and Policies, including the Standards for Commercial Support, regarding industry support of continuing medical education. In order to resolve any identified conflicts of interest, disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships as well as the discussion of unlabeled or unapproved use of any drug, device or procedure by the faculty is listed below.

Zeenat Safdar, MD, serves as a consultant to and is on the speaker's bureau for Actelion, Gilead Sciences, and United Therapeutics. She also serves as a consultant to Pfizer, Inc.

References to off-label usage(s) of pharmaceuticals or instruments in the presentation:
Bosentan, iloprost, epoprostenol (Actelion)
Sildenafil (Pfizer)

Harrison W. Farber, MD, indicates no significant relationships to disclose.

Harold Palevsky, MD, indicates no significant relationships to disclose.

Disclaimer

The information presented in this activity reflects the views of the faculty only and not necessarily those of the Pulmonary Hypertension Association (PHA), College of Medicine, Mayo Clinic, or the educational grant providers. All participants should verify the information and data presented before treating patients or utilizing any therapies noted in these materials. No portion of this activity may be reproduced without the expressed written consent of PHA.

Estimated Time to Complete This Activity

1 hour

Privacy Policy

For information about the PHA's privacy policy, visit http://www.phassociation.org/Page.aspx?pid=193.

This activity is made possible through unrestricted educational grants from Actelion, Gilead, and United Therapeutics.